References
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin and risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973–9
- Ridker PM, Rifai N, Pfeeffer MA, Sacks FM, Moye LA, Goldman S, et al. for the Cholesterol, and Recurrent Events (CARE) Investigators. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839–44
- Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102:2165–8
- Liuzzo G, Biasucci LM, Gallimore JR, Caligiuri G, Buffon A, Rebuzzi AG, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34:1696–1703
- Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou VV, Symeonidis AN, Basayannis EO, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 2002;18:220–8
- Sacks FM, Ridker PM. Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. Hertz 1999;24:51–6
- Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hyper-cholesterolemia. Circulation 2001;103: 1191–3
- Ridker PM, Rifai N, Pfeeffer MA, Sacks FM, Braunwald E, for the Cholesterol, and Recurrent Events (CARE) Investigators. Long-term effect of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100:230–5
- Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998;279:1615–22
- Strandberg TE, Vanhannen H, Tikkanen MJ. Effect statin on C-reactive protein in patient with coronary artery disease. Lancet 1999;353:118–19
- Biasucci LM, Liuzzo G, Grillo RL. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation 1999;99:855–60
- Liuzzo G, Biasucci LM, Gallimore JR. Prognostic value of C-reactive protein and plasma amyloid A protein in severe unstable angina. N Engl J Med 1994;331:417–24
- Riesen WF, Engler H, Risch M, Korte W, Noseda G. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J 2002;23:794–9
- Van de Ree MA, Huisman MV, Princen HM, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003;166:129–35
- Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function and hepatic enzymes. J Cardiovasc Pharmacol Ther 2002;7:219–26
- Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82:67U–73U